Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1946-1953

  Chevalier, Simone ^a   Cury, Fabio L ^b   Scarlata, Eleonora ^a   El Zayat, Ehab ^a   Hamel, Lucie ^a   Rocha, Joice ^a   Zouanat, Fatima Z ^a   Moussa, Sabri ^a   Scherz, Avigdor ^d   Elhilali, Mostafa ^a   Anidjar, Maurice ^a,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Dogs; Photodynamic therapy; Prostate; Prostatic hyperplasia; WST11 compound

Indexed keywords

PADELIPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANINE MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTOURETHROGRAPHY; DIODE LASER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ENDOSCOPIC THERAPY; FOLLOW UP; HISTOPATHOLOGY; ILLUMINATION; INFLAMMATION; MALE; NECROSIS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SIZE; URETHRA PRESSURE; URINE RETENTION; URODYNAMICS; VASCULAR TARGETED PHOTODYNAMIC THERAPY;

EID: 84888638988     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.014     Document Type: Article

References (27)

1. Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011; 95: 87.
2. Tiwari A, Krishna NS, Nanda K et al: Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin Investig Drugs 2005; 14: 1359.
3. Biester K, Skipka G, Jahn R et al: Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority). BJU Int 2012; 109: 722.
4. Elzayat EA and Elhilali MM: Laser treatment of symptomatic benign prostatic hyperplasia. World J Urol 2006; 24: 410.
5. Iagudaev DM, Sorokatyi AE, Martov AG et al: Photodynamic therapy of prostatic adenoma. Urologia 2007; 34.
6. Henderson BW, Waldow SM, Mang TS et al: Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985; 45: 572.
7. Moore CM, Pendse D and Emberton M: Photodynamic therapy for prostate cancerda review of current status and future promise. Nat Clin Pract Urol 2009; 6: 18.
8. Madar-Balakirski N, Tempel-Brami C, Kalchenko V et al: Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One 2010; 5: e10282.
9. Chen Q, Huang Z, Luck D et al: Preclinical studies in normal canine prostate of a novel palladiumbacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol 2002; 76: 438.
10. Gross S, Gilead A, Scherz A et al: Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003; 9: 1327.
11. Brandis A, Mazor O, Neumark E et al: Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 2005; 81: 983.
12. Preise D, Oren R, Glinert I et al: Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 2009; 58: 71.
13. Chevalier S, Anidjar M, Scarlata E et al: Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate. J Urol 2011; 186: 302.
14. Fabre MA, Fuseau E and Ficheux H: Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling. J Pharm Sci 2007; 96: 3444.
15. Berdugo M, Bejjani RA, Valamanesh F et al: Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci 2008; 49: 1633.
16. Moore R: Benign hypertrophy and carcinoma of the prostate. Surgery 1944; 16: 152.
17. Waters DJ, Sakr WA, Hayden DW et al: Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998; 36: 64.
18. Leroy BE and Northrup N: Prostate cancer in dogs: comparative and clinical aspects. Vet J 2009; 180: 149.
19. Leav I, Schelling KH, Adams JY et al: Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001; 48: 210.
20. Berry SJ, Coffey DS and Ewing LL: Effects of aging on prostate growth in beagles. Am J Physiol 1986; 250: R1039.
21. Berry SJ, Strandberg JD, Saunders WJ et al: Development of canine benign prostatic hyperplasia with age. Prostate 1986; 9: 363.
22. Root Kustriz MV: Diseases of the dog and cat. In: Textbook of Veterinary Internal Medicine. Philadelphia: WB Saunders 2000; pp 1690e7.
23. Anidjar M, Scarlata E, Cury FL et al: Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. Prostate 2012; 72: 752.
24. Xiao Z, Dickey D, Owen RJ et al: Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery. J Urol 2007; 178: 308.
25. Ismail AH, Altaweel W, Chevalier S et al: Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol 2004; 11: 2146.
26. Waters DJ, Shen S and Glickman LT: Life expectancy, antagonistic pleiotropy, and the testis of dogs and men. Prostate 2000; 43: 272.
27. Patronek GJ, Waters DJ and Glickman LT: Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 1997; 52: B171.